Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 10/20 | 0.39 |
| ▸ | HSF1 | Q00613 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135539 | 0.81 | EPHX2 (0.53) | MEN1KMT2AEPHX2UCHL1 | |
| SCHEMBL30135547 | 0.79 | DPP4 (0.39) | MEN1KMT2AHSF1DPP4DPP8 | |
| SCHEMBL24928636 | 0.79 | DPP4 (0.39) | MEN1KMT2AHSF1DPP4DPP8 | |
| SCHEMBL6532914 | 0.78 | DPP4 (0.42) | CTSSDPP4DPP8DPP7HTRA1 | |
| SCHEMBL6530127 | 0.76 | DPP4 (0.56) | DPP4DPP8DPP7CYP3A4HTRA1 | |
| SCHEMBL6530249 | 0.75 | DPP4 (0.61) | DPP4DPP8DPP7CYP3A4HTRA1 | |
| SCHEMBL6532393 | 0.75 | DPP4 (0.61) | DPP4DPP8DPP7CYP3A4HTRA1 | |
| SCHEMBL6362125 | 0.74 | HCRTR1 (0.41) | MEN1KMT2A | |
| SCHEMBL6366059 | 0.74 | HCRTR1 (0.41) | MEN1KMT2A | |
| SCHEMBL2709374 | 0.73 | OPRK1 (0.43) | MEN1KMT2AHTRA1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3 B Pharmaceuticals GmbH (DE) | 2024-10-10 | — | — | US | disclosed |
| EP-4373529-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2024-05-29 | — | — | EP | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| EP-4122499-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335569-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | FIBP, FGF2, FGFR2 | MEN1 4311/4885KMT2A 3966/4885CTSS 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.